Regenxbio hits milestone in Duchenne gene therapy ahead of FDA filing
TL;DR Summary
Regenxbio announced its experimental Duchenne muscular dystrophy gene therapy produced sufficient levels of a miniaturized muscle protein in a clinical trial, paving the way for an FDA submission and aiming to improve on Sarepta’s Elevidys in both efficacy and safety, amid ongoing safety concerns surrounding the competitor.
Topics:business#biotechnology#clinical-trials#duchenne-muscular-dystrophy#gene-therapy#healthcare#pharmaceuticals
- Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission statnews.com
- Regenxbio reaps pivotal win for Duchenne gene therapy Fierce Biotech
- Regenxbio Shares Rise After Positive Duchenne Trial Results Yahoo Finance
- REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 PR Newswire
- Regenxbio's Duchenne study succeeded. Will it be enough to convince the FDA? Endpoints News
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
2 min
vs 3 min read
Condensed
90%
494 → 47 words
Want the full story? Read the original article
Read on statnews.com